453 reports of this reaction
3.4% of all EPTINEZUMAB JJMR reports
#6 most reported adverse reaction
FATIGUE is the #6 most commonly reported adverse reaction for EPTINEZUMAB JJMR, manufactured by Lundbeck Pharmaceuticals LLC. There are 453 FDA adverse event reports linking EPTINEZUMAB JJMR to FATIGUE. This represents approximately 3.4% of all 13,519 adverse event reports for this drug.
Patients taking EPTINEZUMAB JJMR who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among EPTINEZUMAB JJMR users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for EPTINEZUMAB JJMR:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 453 FDA reports for EPTINEZUMAB JJMR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.4% of all adverse event reports for EPTINEZUMAB JJMR, making it a notable side effect.
If you experience fatigue while taking EPTINEZUMAB JJMR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.